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Abstract
Aims/hypothesis Polymorphisms in the transcription factor 7-
like 2 (TCF7L2) gene are associated with type 2 diabetes and
reduced insulin secretion. The transcription factor TCF7L2 is
an essential factor for glucagon-like peptide-1 (GLP-1)
secretion from intestinal L cells. We studied whether a
defect in the enteroinsular axis contributes to impaired
insulin secretion in carriers of TCF7L2 polymorphisms.
Methods We genotyped 1,110 non-diabetic German partic-
ipants for five single nucleotide polymorphisms in TCF7L2.
All participants underwent an OGTT; GLP-1 secretion was
measured in 155 participants. In 210 participants, an
IVGTT combined with a hyperinsulinaemic–euglycaemic
clamp was performed. In another 160 participants from the
Netherlands and 73 from Germany, a hyperglycaemic
clamp (10 mmol/l) was performed. In 73 German partic-
ipants this clamp was combined with a GLP-1 infusion and
an arginine bolus.
Results The OGTT data confirmed that variants in TCF7L2
are associated with reduced insulin secretion. In contrast,
insulin secretion induced by an i.v. glucose challenge in the
IVGTT and hyperglycaemic clamp was not different
between the genotypes. GLP-1 concentrations during the
OGTT were not influenced by the TCF7L2 variants.
However, GLP-1-infusion combined with a hyperglycaemic
clamp showed a significant reduction in GLP-1-induced
insulin secretion in carriers of the risk allele in two variants
(rs7903146, rs12255372, p<0.02).
Conclusions/interpretation Variants of TCF7L2 specifically
impair GLP-1-induced insulin secretion. This seems to be
rather the result of a functional defect in the GLP-1
signalling in beta cells than a reduction in GLP-1 secretion.
This defect might explain the impaired insulin secretion in
carriers of the risk alleles and confers the increased risk of
type 2 diabetes.
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Introduction
Genome-wide scans for diabetes susceptibility genes have
been performed in various populations. In early 2006, it was
reported that variants in the transcription factor 7-like 2
(TCF7L2) gene were strongly associated with an increased
risk of type 2 diabetes in an Icelandic, a Danish and a US
population [1]. The estimated population attributable risk of
type 2 diabetes of this variation lies between 10 and 25%,
which is in the range of the peroxisome proliferator-activated
receptor γ gene (PPARγ) Pro12Ala (25% [2]) and the
potassium inwardly-rectifying channel, subfamily J, member
11 gene (KCNJ11) Glu23Lys (15% [3]) polymorphisms.
In the initial report of Grant et al. [1], five single nucleotide
polymorphisms (SNPs) within introns 3 and 4 of the
TCF7L2 gene (rs12255372, rs7903146, rs7901695,
rs11196205, rs7895340) were identified to associate with
an increased risk of type 2 diabetes. This finding initiated a
series of reports in various populations confirming the effect
of these polymorphisms within the TCF7L2 gene on the type 2
diabetes risk [4–12]. Recently, the T allele of rs7903146
was identified as the variant that most strongly determines
the risk of type 2 diabetes [13]. In carriers of the risk alleles
for SNPs within TCF7L2 several studies additionally
showed an impaired insulin secretion estimated from an
OGTT or IVGTT [6, 7, 9, 10]. These studies indicate that
progressive loss of insulin secretion might be the essential
component of the phenotype which predisposes carriers of
the TCF7L2 variant to develop type 2 diabetes. The
pathogenic mechanism of the impaired insulin secretion
due to polymorphisms in the TCF7L2 gene is not yet clear.
It could be the consequence of a reduction in beta cell mass
or could reflect a dysfunction of pancreatic beta cells.
Furthermore, a defect in incretin-induced stimulus secretion
coupling could mediate a reduction of insulin secretion in
carriers of the TCF7L2 polymorphisms. The latter hypoth-
esis is supported by the molecular mode of action of the
transcription factor TCF7L2. TCF7L2 is an essential com-
ponent of the wingless-type MMTV integration site family,
member 1 (WNT) signalling pathway, which is crucial for
the regulation of the glucagon gene (GCG) expression and
the secretion of its product GLP-1 by the intestinal
endocrine L cells [14]. Therefore, an alteration in the WNT
signalling pathway through polymorphisms in the TCF7L2
gene might result in an altered GLP-1 response, which in
turn could lead to a lower postprandial insulin secretion.
To test this hypothesis we analysed the associations of
the above-described TCF7L2 polymorphisms with basal
GLP-1 secretion and glucose-induced GLP-1 response
during an OGTT in non-diabetic participants. We further
studied the influence of the TCF7L2 SNPs on insulin
secretion kinetics to i.v. administered glucose during an
IVGTT and a hyperglycaemic clamp. In addition, we
particularly investigated the influence on GLP-1-induced
insulin secretion using a combined hyperglycaemic clamp
with additional GLP-1 infusion and arginine bolus [15].
Methods
Participants We studied 1,110 non-diabetic participants by
an OGTT (Table 1). Secretion patterns of GLP-1 were
obtained in a subgroup of 155 participants. The anthropo-
metric characteristics of this subgroup are shown in Table 2.
All 1,110 participants were also genotyped for the
following five SNPs in the TCF7L2 gene: rs7903146,
rs12255372, rs7901695, rs11196205 and rs7895340.
A subset of 210 participants were studied by an IVGTT
combined with a euglycaemic–hyperinsulinaemic clamp to
determine insulin secretion capacity and insulin sensitivity
in one test [16] (Table 3).
Additionally, 233 participants were studied by a hyper-
glycaemic clamp [17]. The participants were selected from
three independent studies in the Netherlands and Germany.
The German and the Dutch cohort from Utrecht consisted of
NGT and IGT participants, the Dutch cohort from Hoorn
consisted of IGT participants only (Table 4). All participants
in our studies underwent a standard OGTT to define their
glucose tolerance status. Details of the study groups have
been described previously [17–19]. In the German subgroup
(n=73), the hyperglycaemic clamp was continued with an
additional GLP-1 and arginine administration [15, 20–22].
The participants were not related to each other. Informed
written consent for all studies was obtained from all
participants, and the local ethics committee approved the
protocols.
Genotyping Detection of the TCF7L2 polymorphisms
described by Grant et al. [1] was done using the TaqMan
assay (Applied Biosystems, Forster City, CA, USA) in the
German population. The TaqMan genotyping reaction was
amplified on a GeneAmp PCR system 7000, and fluores-
cence was detected on an ABI PRISM 7000 sequence
detector (Applied Biosystems). As a quality standard, we
randomly included six positive (two homozygous wild-type
allele carriers, two heterozygous and two homozygous risk
allele carriers) and two negative (all components excluding
DNA) sequenced controls in each TaqMan reader plate.
Because all controls were correctly identified, we assumed
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that the genotyping error rate of this method did not exceed
0.3% [23].
In the Dutch population, only rs7903146 was determined
using an ABI PRISM 7900HT sequence detector (Applied
Biosystems).
OGTT At 08:00 hours, participants ingested a solution
containing 75 g glucose. Venous blood samples were
obtained at 0, 30, 60, 90 and 120 min for determination
of plasma glucose, insulin and C-peptide concentrations
and 0, 30 and 120 min for determination of GLP-1
concentrations. The participants did not take any medica-
tion known to affect glucose tolerance or insulin sensitivity.
Tests were performed after an overnight fast of 12 h.
Combined IVGTT and hyperinsulinaemic–euglycaemic
clamp After an overnight fast and after baseline samples
had been obtained, 0.3 g/kg bodyweight of a 20% (vol./vol.)
glucose solution was given at time 0. Blood samples for the
measurement of plasma glucose, plasma insulin and C-peptide
were obtained at 2, 4, 6, 8, 10, 20, 30, 40, 50 and 60min. After
60 min, a priming dose of insulin was given followed by an
infusion (40 mU/m2) of short-acting human insulin for
120 min. A variable infusion of 20% glucose was started to
maintain the plasma glucose concentration at 5.5 mmol/l.
Blood samples for the measurement of plasma glucose were
obtained at 5 min intervals throughout the clamp.
Hyperglycaemic clamp Hyperglycaemic clamps were per-
formed at 10 mmol/l in all participants. The Dutch NGT
and IGT participants underwent a 3 h clamp. In the German
NGT participants, the clamp lasted for 2 h followed by the
GLP-1 and arginine stimulation (see below). After an
overnight fast, the participants received an i.v. glucose
bolus to acutely raise glucose levels to 10 mmol/l. Plasma
glucose levels were measured at the appropriate intervals to
maintain a constant plasma glucose during the clamp.
Blood samples for insulin were drawn at 2.5 min intervals
during the first 10 min of the clamp and at 10–20 min
intervals during the remainder. Exact details of the clamp-
ing procedures in the different study groups have been
described previously [15, 18, 19].
Combined hyperglycaemic clamp This hyperglycaemic
clamp combined with GLP-1 and arginine administration
was performed as previously described [15, 20–22]. After
120 min of hyperglycaemic clamp at 10 mmol/l, a bolus of
GLP-1 (0.6 pmol/kg) was given (human GLP-1(7-36)
amide; Poly Peptide, Wolfenbüttel, Germany) followed by
a continuous GLP-1 infusion (1.5 pmol kg−1 min−1) during
the next 80 min. At 180 min, a bolus of 5 g arginine
hydrochloride (Pharmacia & Upjohn, Erlangen, Germany)
was injected over 45 s while the GLP-1 infusion was
continued. Blood for the measurement of glucose, insulin,
proinsulin and C-peptide was obtained during the time-
points shown in Fig. 1. This clamp allows measurement of
different aspects of stimulus secretion coupling: first and
second phases of glucose-induced insulin secretion, GLP-1-
induced insulin secretion, and the response to additional
arginine administration.
Analytical procedures Plasma glucose was determined as
previously described [14, 17, 20, 21]. GLP-1 was deter-
mined during the OGTT at baseline, 30 and 120 min. GLP-1
immunoreactivity was determined using an RIA specific for
the C-terminus of the peptide [24]. Samples were stored at
−80°C. The assay measures the sum of the intact peptide
plus the primary metabolite, GLP-1(9–36)amide using
the polyclonal anti-GLP-1 antibody 89390 and synthetic
GLP-1(7–36)amide as standard.
Plasma insulin and C-peptide concentrations in the German
cohort were measured by a microparticle enzyme immunoas-
say (Abbott, Wiesbaden, Germany) and an RIA (Byk-Santec,
Dietzenbach, Germany). In the participants from the Nether-
lands, insulin was measured using an in-house competitive
RIA employing a polyclonal anti-insulin antibody (Caris 46),
125I-labelled insulin (IM 166; Amersham, Roosdaal, the
Netherlands) as a tracer and regular insulin (Humulin; Eli
Lilly, Indianapolis, IN, USA) as a standard.
Calculations Insulin secretion in the OGTT was assessed
by calculating the AUC for C-peptide divided by the AUC
for glucose (AUCCP/AUCGlc). AUCs were determined by
the trapezoidal method. Furthermore, insulin secretion was
calculated as insulin:glucose ratio by dividing (insulin at
30 min–insulin at 0 min) by (glucose at 30 min–glucose at
0 min). Insulin sensitivity during the OGTT was estimated
from glucose and insulin values as proposed by Matsuda
and DeFronzo [25].
Insulin secretion during the IVGTT was calculated as
the sum of C-peptide levels during the first 10 min after
glucose administration. Insulin sensitivity during the
hyperinsulinaemic–euglycaemic clamp was calculated by
dividing the average glucose infusion rate during the last
40 min of the clamp by the average plasma insulin
concentration during the same time interval.
Insulin secretion during the hyperglycaemic clamp was
calculated using insulin levels determined during the
clamp. The first phase of insulin secretion was defined as
the sum of the insulin levels during the first 10 min of the
clamp. The second phase of insulin secretion was defined
as the mean of the insulin values during the last 40 min
(80–120 min, NGT group, Germany) or the last 30 min
(150–180 min, NGT and IGT groups, the Netherlands) of
the clamp.
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In the combined hyperglycaemic clamp with GLP-1 and
arginine administration, first-phase GLP-1-induced insulin
secretion was defined as the mean of the 125 and 130 min
insulin levels, second-phase GLP-induced insulin secretion
(plateau) was defined as the mean of the 160–180 min
insulin levels. The acute insulin response to arginine was
calculated as the mean of 182.5 and 185 min minus
180 min insulin levels [21].
The insulin sensitivity index was determined by relating
the glucose infusion rate to the plasma insulin concentration
during the last 40 min (NGT, Germany) or 30 min of the
clamp.
Statistical analysis Data are given as means±SEM. Non-
normally distributed parameters were logarithmically trans-
formed to approximate linearity for statistical comparison.
Distribution was tested for normality using the Shapiro–
Wilk W test. Differences in anthropometrics and metabolic
characteristics between genotypes were tested using
ANOVA for the three genotype groups. The secretion
indices were compared using multivariate regression mod-
els. In these models the trait was the dependent variable
whereas age, sex, insulin sensitivity and genotype were the
independent variables. Due to the relatively low number of
participants who were homozygous for the rare alleles in
the hyperglycaemic clamp group, a dominant model was
used. A p value of <0.05 was considered to be statistically
significant. The statistical software package JMP (SAS
Institute, Cary, NC, USA) was used.
Results
Genetic variants in the TCF7L2 gene The SNPs described
in the paper of Grant et al. [1] had an allelic frequency of
the minor allele of 30% (rs7903146), 28% (rs12255372),
31% (rs7901695), 46% (rs11196205) and 45% (rs7895340)
in our population. These polymorphisms were all in
Hardy–Weinberg equilibrium and in linkage disequilibrium
(Electronic supplementary material Table 1).
OGTT: glucose tolerance, insulin secretion, insulin sensi-
tivity and GLP-1 levels The percentage of participants with
IGT was significantly higher in carriers of the risk allele for
rs7903146 (p=0.007), rs12255372 (p=0.02) and rs7901695
(p=0.02).
Insulin secretion assessed as AUCCP/AUCGlc during the
OGTT was significantly reduced in participants with the
risk alleles for rs7903146 and rs12255372 in the additive
and dominant model both unadjusted and adjusted for
relevant covariates. Participants with the risk allele for
rs7901695 had a significantly decreased insulin secretion
in the additive model (p=0.02) (Table 1).
Insulin sensitivity, estimated by the index of Matsuda
and DeFronzo [25], was significantly higher in participants
carrying the risk alleles for rs7903146 and rs1255372 in
TCF7L2 (Table 1).
In a subgroup of 155 participants we measured GLP-1
concentrations at baseline, at 30 min and 120 min after
oral ingestion of 75 g glucose. The anthropometric
characteristics are shown in (Table 1). Neither basal
GLP-1 plasma levels nor GLP-1 levels during the OGTT
significantly differed between the genotypes in any of the
above-described SNPs in the TCF7L2 gene (Table 2).
Combined IVGTT and hyperinsulinaemic–euglycaemic
clamp: glucose-induced insulin secretion and insulin
sensitivity C-peptide and insulin values during the IVGTT
were not significantly different between the genotypes in
any of the above-described SNPs in the TCF7L2 gene.
Table 3 shows the results for rs7903146 in the additive and
dominant model adjusted for relevant covariates. Includ-
ing the glucose tolerance status as an additional co-variate
in the model did not affect the results. Interestingly, a
lower insulin secretion in this subgroup of participants
could be demonstrated when insulin secretion was calcu-
lated from the OGTT as described above (Table 3). Insulin
sensitivity measured with the clamp technique was not
affected by any of the genotypes (all p>0.4).
Hyperglycaemic clamp: glucose-, GLP-1- and arginine-
induced insulin secretion and insulin sensitivity First- and
second-phase insulin secretion during the hyperglycaemic
clamp were not significantly different between carriers
and non-carriers of the risk allele for rs7903146 (Table 4)
in any of the three populations from the Netherlands and
from Germany. The other four SNPs in TCF7L2 which
were described above were determined in the German
population only and were not associated with glucose-
induced insulin secretion (data not shown) during the
hyperglycaemic clamp.
The first phase of GLP-1-induced insulin secretion
was significantly reduced in carriers of the risk alleles for
rs7903146 (p=0.03) and rs12255372 (p=0.02). In addi-
tion, we found significant differences in the second phase
of GLP-1-induced insulin secretion for rs7903146 (p=
0.006), rs12255372 (p=0.005) and rs7901695 (p=0.02)
with carriers of the risk alleles having a significantly lower
second phase of GLP-1-induced insulin secretion. Table 4
and Fig. 1 show the results for SNP rs7903146.
In contrast to GLP-1-induced insulin secretion, argi-
nine-induced insulin secretion was not affected by any of
the analysed SNPs in TCF7L2 (Table 4).
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Table 2 Anthropometric and metabolic data of the subgroup of 155 participants with additional measurements of GLP-1
rs7903146 p value (ANOVA) p value (CC vs XT)
Genotype C/C C/T T/T
n 73 67 15
NGT/IGT 64/9 48/19 10/5 0.03 0.009
Sex (female/male) 50/23 42/25 8/7 0.50 0.33
Age (years) 46±1 47±1 47±3 0.99 0.96
BMI (kg/m2) 29.8±0.7 30.3±0.7 27.1±1.1 0.15 0.88
Plasma glucose (mmol/l)
Fasting 5.2±0.05 5.3±0.07 5.6±0.2 0.17 0.21
2 h 6.5±0.1 7.0±0.2 7.2±0.5 0.22 0.10
Insulin sensitivityOGTT (arbitrary units) 12.8±0.7 13.6±1.0 15.7±2.6 0.74/0.92
a 0.78/0.75a
Insulin secretionOGTT (pmol/mmol) 304±12 287±13 235±19 0.01/0.02
b 0.02/0.01b
GLP-1 (pmol/l)
0 min 16.1±0.9 17.3±1.3 17.3±2.0 0.91 0.88
30 min 34.1±2.1 38.8±4.0 38.1±3.5 0.45 0.36
120 min 28.9±1.5 29.0±1.7 28.9±2.4 0.87 0.88
Fold increase 0–30 min 2.5±0.2 2.7±0.3 2.4±0.4 0.77 0.84
Data are means±SEM
p values were obtained using χ2 test or ANOVA
Analysis for rs7901695 also revealed a significant difference in insulin secretion (p=0.02), whereas for rs7895340 and rs11196205 no significant
differences in insulin secretion were detected (p=0.73 and 0.76)
a p values were derived from multivariate linear regression models: adjusted for age, sex and BMI
b p values were derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivity
Table 1 Anthropometric and metabolic data from all 1,110 participants who underwent an OGTT
rs7903146 p value (ANOVA) p value (CC vs XT)
Genotype C/C C/T T/T
n 546 474 90
NGT/IGT 461/85 386/88 63/27 0.007 0.03
Sex (female/male) 346/200 315/159 50/40 0.13 0.64
Age (years) 39±1 40±1 41±1 0.39 0.67
BMI (kg/m2) 29.5±0.4 28.9±0.4 28.2±1.0 0.51 0.24
Plasma glucose (mmol/l)
Fasting 5.1±0.02 5.1±0.02 5.2±0.07 0.25 0.39
2 h 6.1±0.07 6.2±0.07 6.7±0.2 0.06 0.17
Plasma insulin (pmol/l)
Fasting 62.0±2.1 53.4±1.7 49.8±3.1 0.004 0.001
2 h 442±19 356±17 372±34 0.12 0.04
Insulin sensitivityOGTT (arbitrary units) 16.8±0.5 18.2±0.5 17.8±1.2 0.02/0.02
a 0.005/0.006a
Insulin secretionOGTT (pmol/mmol) 319±5 301±5 292±10 0.003/0.04
b 0.0009/0.02b
Insulin/glucose ratio (pmol/mmol) 143±5 127±5 124±13 0.003/0.03b 0.001/0.01b
Data are means±SEM
p values were obtained using χ2 test or ANOVA
Analysis for rs12255372 and rs7901695 also revealed a significant difference in insulin secretion (p=0.003 and p=0.05), whereas for rs7895340
and rs11196205 no significant differences in insulin secretion were detected (p=0.53 and 0.45)
a p values are derived from multivariate linear regression models: adjusted for age, sex and BMI
b p values are derived from multivariate linear regression models: adjusted for age, sex, BMI and insulin sensitivity
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Table 4 Anthropometric and metabolic data of 233 participants who underwent a hyperglycaemic clamp and of 73 participants who underwent a
modified hyperglycaemic clamp with additional GLP-1 and arginine administration
Germany The Netherlands (Utrecht) The Netherlands (Hoorn)
rs7903146 p value rs7903146 p value rs7903146 p value
Genotype C/C X/T C/C X/T C/C X/T
Sex (female/male) 15/20 24/14 0.08 5/31 22/11 <0.01 17/11 30/33 0.27
NGT/IGT 30/5 27/11 0.13 31/5 26/7 0.53 0/28 0/66 –
Age (years) 38±2 40±2 0.66 47±1 47±1 0.94 56±1 58±1 0.43
BMI (kg/m2) 26.1±0.9 25.1±0.6 0.41 25.6±0.7 26.2±0.7 0.49 29.2±0.8 27.9±0.4 0.13
Plasma glucose (mmol/l)
Fasting 5.1±0.1 5.0±0.1 0.72 4.6±0.1 4.8±0.1 0.18 6.6±0.1 6.6±0.1 0.75
2 h glucose 5.9±0.3 6.5±0.3 0.21 5.7±0.3 5.6±0.3 0.74 9.5±0.1 9.5±0.1 0.84
Insulin sensitivity (μmol kg−1
min−1 [pmol/l]−1)
0.15±0.02 0.15±0.01 0.90 0.17±0.02 0.18±0.02 0.60 0.11±0.01 0.14±0.01 0.21
Insulin secretion index (pmol/l)a
First phase (sum 0–10 min) 1,067±158 815±105 0.18 963±75 891±96 0.76 699±70 679±72 0.68
Second phase 308±47 291±41 0.80 389±42 376±47 0.71 304±45 303±38 0.18
First phase GLP-1 2,049±258 1,466±175 0.03 n.a. n.a. n.a. n.a.
Second phase GLP-1 4,567±568 2,881±341 0.006 n.a. n.a. n.a. n.a.
Arginine 2,680±226 2,252±181 0.40 n.a. n.a. n.a. n.a.
Data are means±SE
p values were obtained using χ2 test, unpaired t test or multivariate linear regression models
Carriers of the risk allele for SNP rs12255372 showed reduced first phase (p=0.02) and second phase (p=0.005) GLP-1-induced insulin secretion
Carriers of the risk allele for SNP rs7901695 showed reduced second phase (p=0.02) GLP-1-induced insulin secretion
n.a. Not available
a Adjusted for age, sex and BMI, and insulin sensitivity
Table 3 Anthropometric and metabolic data of 210 participants who
underwent a combined IVGTTand hyperinsulinaemic–euglycaemic clamp
rs7903146 p value
(CC vs XT)
Genotype C/C X/T
n 97 113
NGT/IGT 80/17 81/32 0.06
Sex (female/male) 59/38 64/49 0.58
Age (years) 44±1 45±1 0.29
BMI (kg/m2) 29.0±0.5 28.8±0.5 0.82
Insulin sensitivityclamp
(μmol kg−1 min−1
[pmol/l]−1)
0.07±0.01 0.07±0.01 0.77
Insulin secretion indexa
IVGTT C-peptide secretion
(pmol/l)
7,904±306 7,679±323 0.40
IVGTT insulin secretion (pmol/l) 2,059±131 1,924±129 0.25
OGTT insulin secretion
(pmol/mmol)
314±8 292±8 0.04
Data are means±SEM
p values were obtained using χ2 test or unpaired t test or multivariate
linear regression models
None of the four other SNPs in TCF7L2 (rs12255372, rs7901695,
rs11196205 and rs7895340) affected significantly insulin secretion in
the IVGTT (all p>0.2)
a Adjusted for age, sex and BMI, and insulin sensitivity
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Fig. 1 Associations between the genotypes of rs7903146 polymor-
phism in the TCF7L2 gene with insulin secretion during a hyper-
glycaemic clamp in 73 German participants. Open circles CC; closed
circles CT and TT. AIR Acute insulin response. Arrow Administration
of 5 g arginine. The p values show the differences for first and second
phases of glucose-induced insulin secretion, first and second phases of
GLP-1-induced insulin secretion and acute insulin secretory response
to arginine (AIR) (for calculation see ‘Methods’; insulin secretion is
adjusted for insulin sensitivity)
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Discussion
The variants in TCF7L2 described by Grant et al. [1] that
mediate an increased risk of type 2 diabetes have been found
to be associated with reduced insulin secretion [6, 7, 9, 10].
We could confirm this reduced insulin secretion in our study
in a group of 1,110 German non-diabetic participants using C-
peptide levels during an OGTT. Unexpectedly, the i.v.
application of glucose during an IVGTT did not affect insulin
secretion in carriers of the risk alleles for SNPs in TCF7L2.
The same results were obtained using i.v. glucose challenge
during a hyperglycaemic clamp in subgroups of the German
population and a population from the Netherlands. The
observed different results between an orally and i.v. adminis-
tered glucose challenge generate the hypothesis that incretin-
induced insulin secretion is affected by the variants in the
TCF7L2 gene. Possible mechanisms explaining these findings
include impaired incretin production or incretin signalling.
To address this issue we first measured basal GLP-1
concentrations and GLP-1 response during an OGTT. None
of the tested variants that have been shown in the literature
to exert a reproducible effect on type 2 diabetes were
associated with basal GLP-1 levels or with GLP-1 response
during the OGTT.
Furthermore, we combined the hyperglycaemic clamp
with additional GLP-1 infusion to measure GLP-1-induced
insulin secretion. Both acute (so called first phase) and
prolonged (so called second phase) GLP-1-induced insulin
secretion during the hyperglycaemic clamp were signifi-
cantly impaired in carriers of the risk alleles in TCF7L2.
These data suggest that participants carrying the risk alleles
have an impaired insulin secretion due to an impairment of
the GLP-1 signalling chain.
The putative molecular mechanism for this finding is not
clear. As the transcription factor TCF7L2 plays an essential
role in the WNT signalling pathway [14], which on the one
hand is required for a normal development of the pancreas
and the pancreatic islets [26] and on the other hand is
crucial for the regulation of GLP-1 expression and secretion
in intestinal L cells [14]. In theory, polymorphisms in the
TCF7L2 gene might therefore through alteration of the
WNT signalling pathway directly affect beta cell growth,
beta cell differentiation and beta cell function. Furthermore
insulin secretion might also be affected indirectly via the
enteroinsular axis either through an impaired overall GLP-1
secretion or through a defective or dysfunctional GLP-1-
induced insulin secretion. An impaired or dysfunctional
GLP-1 effect might result first in a reduced postprandial
insulin secretion and second, might influence stimulation of
beta cell growth and beta cell differentiation.
Our data show that basal and glucose-induced GLP-1
secretion during the OGTT were not affected by any of the
analysed SNPs, whereas the first and second phases of
GLP-1-induced insulin secretion were significantly reduced
in carriers of the risk alleles in three of the five above-
described SNPs in the TCF7L2 gene, among them
rs7903146, which is most strongly associated in the
literature with type 2 diabetes [1, 6, 9, 12, 13]. The finding
that basal and glucose-stimulated GLP-1 secretion were not
influenced by the TCF7L2 polymorphisms indicates that a
reduced GLP-1 secretion is not likely to explain the
impaired insulin secretion in carriers of the risk genotypes,
although it can not fully exclude an effect of these SNPs on
GLP-1 levels. First, by measuring total GLP-1 levels, we
may have missed a subtle defect in GLP-1 secretion, which
may have been detected by measuring the active form of
GLP-1. Second, systemic GLP-1 levels may not adequately
reflect the level of the active hormone acting in the gut wall
on the autonomic nervous system [27]. Third, impaired
TCF7L2 activity might tissue-specifically reduce the GLP-1
levels in the brain, which are believed as well to be
important for insulin secretion [28].
While we have no evidence for reduced GLP-1 secretion
we have strong evidence for an impaired GLP-1-induced
insulin secretion in carriers of the above-described poly-
morphisms in TCF7L2. The data show a reduced efficiency
of GLP-1 to stimulate insulin secretion in pancreatic beta
cells. Alterations of the GLP-1 signalling pathway in beta
cells might thereby play a role. Recently the TCF7L2 gene
was also identified in human pancreas [14]. Therefore
variations in this transcription factor could specifically
impair the transcription of genes involved in the incretin
signalling chain, resulting in resistance of the pancreatic
beta cells to GLP-1.
In contrast to the observed reduction in the first and second
phases of GLP-1-induced insulin secretion, the arginine-
induced insulin secretion was not significantly affected by the
analysed SNPs in the TCF7L2 gene. The arginine bolus in
the combined hyperglycaemic clamp produces a maximal
challenge for the secretory capacity of the beta cell and can
be considered as a surrogate for beta cell mass [15, 20]. The
SNPs do not affect this maximal insulin secretion, suggest-
ing that the variants in TCF7L2 do not influence beta cell
mass, at least in the prediabetic state. In addition, impaired
beta cell function may also include the efficiency of the
conversion from proinsulin to insulin [21]. However, there
was no evidence for this abnormality related to the variants
in the TCF7L2 gene during the hyperglycaemic clamp (data
not shown).
We also found that insulin sensitivity calculated from the
OGTT using an established index [25] was significantly
increased in participants carrying the risk alleles for all
analysed SNPs in the TCF7L2 gene. This was also
described in the study of Florez et al. [9]. When we
measured insulin sensitivity with the gold standard, the
euglycaemic–hyperinsulinaemic clamp and the hypergly-
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caemic–hyperinsulinaemic clamp, we found no association
of the risk alleles with insulin sensitivity. Taken together,
our data suggest that the variants in the TCF7L2 gene do
not have a strong effect on insulin sensitivity.
In summary, our data show that variations in the TCF7L2
gene are associated with impaired GLP-1-induced insulin
secretion. This might be consistent with a state of relative
incretin resistance. Increasing the incretin levels by pharma-
cological tools may thus be a logical therapy to overcome
impaired insulin secretion in carriers of the TCF7L2 variants.
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